ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 45 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,010 | +11.4% | 2,621 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $26,944 | +83.7% | 2,621 | +37.9% | 0.00% | 0.0% |
| Q1 2023 | $14,668 | +95.9% | 1,900 | +108.6% | 0.00% | – |
| Q4 2022 | $7,488 | +24.8% | 911 | 0.0% | 0.00% | – |
| Q3 2022 | $6,000 | -14.3% | 911 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | -12.5% | 911 | 0.0% | 0.00% | – |
| Q1 2022 | $8,000 | -38.5% | 911 | 0.0% | 0.00% | – |
| Q4 2021 | $13,000 | +30.0% | 911 | 0.0% | 0.00% | – |
| Q3 2021 | $10,000 | +25.0% | 911 | 0.0% | 0.00% | – |
| Q2 2021 | $8,000 | – | 911 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |